Loading...
XTAI1760
Market cap213mUSD
Dec 25, Last price  
81.40TWD
1D
-0.61%
1Q
-8.64%
Jan 2017
20.06%
Name

Panion & BF Biotech Inc

Chart & Performance

D1W1MN
XTAI:1760 chart
P/E
90.38
P/S
3.71
EPS
0.90
Div Yield, %
2.46%
Shrs. gr., 5y
2.04%
Rev. gr., 5y
5.96%
Revenues
1.88b
-21.54%
559,396,000524,779,000584,249,000674,896,000857,082,0001,014,406,0001,205,065,0001,049,246,0001,212,478,0001,408,741,0001,573,944,0001,568,637,0001,901,211,0002,398,648,0001,881,875,000
Net income
77m
-57.65%
5,088,000-39,305,000-36,260,000-40,562,00018,149,00048,269,00072,996,00089,720,00090,539,000159,171,000161,329,00027,901,000104,402,000182,345,00077,219,000
CFO
177m
-63.78%
76,978,000-13,895,000-36,120,0003,958,00086,225,00076,111,00058,304,000177,217,000113,973,00078,584,00090,984,000-14,555,000401,225,000489,872,000177,418,000
Dividend
Jun 13, 20241.5 TWD/sh
Earnings
Mar 05, 2025

Profile

Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures and sells various pharmaceutical products in Taiwan. The company offers products in the areas of medical beauty, kidney, respiratory tract, gastrointestinal tract, and body and hair cleaning. It also provides oral drugs and topical preparations; hand and mechanical disinfection, body lotion, and skin disinfection products; and pet health products, including surgical and skin prescriptions. Panion & Bf Biotech Inc. was founded in 1976 and is headquartered in Taipei, Taiwan.
URL
https://www.pbf.com.tw/
IPO date
Jun 14, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,881,875
-21.54%
2,398,648
26.16%
1,901,211
21.20%
Cost of revenue
1,726,098
1,984,606
1,733,779
Unusual Expense (Income)
NOPBT
155,777
414,042
167,432
NOPBT Margin
8.28%
17.26%
8.81%
Operating Taxes
91,492
151,064
78,250
Tax Rate
58.73%
36.49%
46.74%
NOPAT
64,285
262,978
89,182
Net income
77,219
-57.65%
182,345
74.66%
104,402
274.19%
Dividends
(171,478)
(128,609)
(53,717)
Dividend yield
1.78%
0.84%
0.90%
Proceeds from repurchase of equity
2,566,900
BB yield
-43.08%
Debt
Debt current
580,207
424,634
334,719
Long-term debt
199,699
122,128
252,809
Deferred revenue
17,477
Other long-term liabilities
52,527
34,048
20,345
Net debt
177,738
7,408
224,398
Cash flow
Cash from operating activities
177,418
489,872
401,225
CAPEX
(181,231)
(198,644)
(170,008)
Cash from investing activities
(155,274)
(144,466)
(215,049)
Cash from financing activities
48,667
(167,388)
(217,760)
FCF
(45,935)
306,783
53,778
Balance
Cash
534,625
464,257
348,890
Long term investments
67,543
75,097
14,240
Excess cash
508,074
419,422
268,069
Stockholders' equity
1,049,673
1,141,419
1,034,739
Invested Capital
2,183,366
2,076,907
2,199,918
ROIC
3.02%
12.30%
4.02%
ROCE
5.63%
16.11%
6.59%
EV
Common stock shares outstanding
85,791
85,828
79,236
Price
112.00
-37.43%
179.00
138.03%
75.20
-11.63%
Market cap
9,608,592
-37.46%
15,363,212
157.83%
5,958,547
-10.15%
EV
9,786,330
15,370,620
6,182,945
EBITDA
326,167
577,589
311,055
EV/EBITDA
30.00
26.61
19.88
Interest
11,357
7,585
14,681
Interest/NOPBT
7.29%
1.83%
8.77%